Antihistamines as an early treatment for Covid-19

Blanco, Juan Ignacio Morán; Bonilla, Judith A. Alvarenga; Fremont-Smith, Philip; Heras, Karina Villar Gómez de las

doi:10.1016/j.heliyon.2023.e15772

Cited by 8 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, drugs targeting MCs and their products are promising as a therapeutic strategy to prevent severe clinical courses in DENV infection and may bear similar promise in preventing severe COVID-19, which warrants further evaluation. While retrospective studies suggest that antihistamine use may influence COVID-19 hospitalization rates ( 64 , 65 ), and a trial of Histamine-1/Histamine-2 receptor blockade in patients with COVID-19 suggested some improvements in lung function ( 66 ), histamine is only one product produced by MCs and it is also produced by many other cell types during inflammation ( 14 ). A trial involving combination therapy of the MC-stabilizing drug ketotifen with the NSAID indomethacin is also underway (NCT05007522) and this may shed light on the potential of broadly targeting MC functions to improve COVID-19 outcomes.…”

Section: Discussionmentioning

confidence: 99%

Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19

Tan¹,

Anderson²,

Rathore³

et al. 2023

Journal of Clinical Investigation

View full text Add to dashboard Cite

Lung inflammation is a hallmark of Coronavirus disease 2019 (COVID-19) in patients who are severely ill, and the pathophysiology of disease is thought to be immune mediated. Mast cells (MCs) are polyfunctional immune cells present in the airways, where they respond to certain viruses and allergens and often promote inflammation. We observed widespread degranulation of MCs during acute and unresolved airway inflammation in SARS-CoV-2-infected mice and nonhuman primates. Using a mouse model of MC deficiency, MC-dependent interstitial pneumonitis, hemorrhaging, and edema in the lung were observed during SARS-CoV-2 infection. In humans, transcriptional changes in patients requiring oxygen supplementation also implicated cells with a MC phenotype in severe disease. MC activation in humans was confirmed through detection of MC-specific proteases, including chymase, the levels of which were significantly correlated with disease severity and with biomarkers of vascular dysregulation. These results support the involvement of MCs in lung tissue damage during SARS-CoV-2 infection in animal models and the association of MC activation with severe COVID-19 in humans, suggesting potential strategies for intervention.

show abstract

Section: Discussionmentioning

confidence: 99%

Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19

Tan¹,

Anderson²,

Rathore³

et al. 2023

Journal of Clinical Investigation

View full text Add to dashboard Cite

show abstract

Predictive models of long COVID

Antony,

Blau,

Casiraghi

et al. 2023

eBioMedicine

View full text Add to dashboard Cite

Effects of pharmacotherapy on post-COVID-19 pulmonary fibrosis: Systemic review

Butranova,

Baybulatova,

Zyryanov

et al. 2024

BIO Web Conf.

View full text Add to dashboard Cite

Pulmonary fibrosis is one of serious consequences of COVID-19. Its prevalence and risk factors including disease severity, length of mechanical ventilation and hospitalization were studied, but the effect of pharmacotherapy was not widely assessed. This systematic review is aimed to investigate potential effects of drugs used before and during COVID-19 on lung damage possibly leading to pulmonary fibrosis, and effects of post-COVID-19 therapy used to fight formed pulmonary fibrosis. PubMed database was searched to identify studies published in English up to February 10, 2024. The systematic search revealed a total of 580 full-text articles, of which 23 (results of clinical trials) were finally included in the analysis. Most works considering COVID-19 treatment highlighted antibiotics and corticosteroids as groups with the highest frequency of use in patients with negative clinical outcomes and respiratory function decline, suggesting possible negative effects on pulmonary fibrosis development. Pre-COVID-19 treatment revealed rituximab and chemotherapy as main drug factors associated with pulmonary fibrosis development, and post-COVID-19 therapy with antifibrotic drugs revealed discussible results. Our systematic review was an attempt to highlight possible effects of pharmacotherapy on the lung damage leading to the pulmonary fibrosis formation.

show abstract

Antihistamines as an early treatment for Covid-19

Cited by 8 publications

References 35 publications

Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19

Mast cell activation in lungs during SARS-CoV-2 infection associated with lung pathology and severe COVID-19

Predictive models of long COVID

Effects of pharmacotherapy on post-COVID-19 pulmonary fibrosis: Systemic review

Contact Info

Product

Resources

About